NDAINTRAVENOUSPOWDER
Approved
Mar 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
6/8 — Strong
KIMYRSA (oritavancin diphosphate) by CorMedix is 12. Approved for skin structure infections (absssi) caused by susceptible isolates of the following gram-positive microorganisms: staphylococcus aureus (including methicillin-susceptible, methicillin-resistant isolates), streptococcus pyogenes and 3 more indications. First approved in 2021.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KIMYRSA is a lipoglycopeptide antibiotic (oritavancin diphosphate) administered as a single 1,200 mg IV dose for acute bacterial skin and skin structure infections (ABSSSI) caused by gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA). The drug binds to bacterial cell wall precursors and disrupts cell wall synthesis, with pharmacodynamic activity correlating to AUC/MIC ratios. Its long half-life (~245 hours) enables single-dose therapy, a major competitive advantage in the crowded ABSSSI market.
$0.001BPart D
Peak9.2 years to LOEProduct is in peak lifecycle with minimal Part D utilization ($1M spending, 198 claims in 2023), suggesting limited commercial traction and likely small brand team relative to legacy competitors.
Mechanism of Action
12.1 Mechanism of Action Oritavancin is an antibacterial drug [see ] . 12.2 Pharmacodynamics The antimicrobial activity of oritavancin appears to correlate with the ratio of area under the concentration-time curve to minimal inhibitory concentration (AUC/MIC) based on animal models of infection.…
Worked on KIMYRSA at CorMedix? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.